A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

BACKGROUND: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahma, Osama E, Ashtar, Ed, Ibrahim, Ramy, Toubaji, Antoun, Gause, Barry, Herrin, Vincent E, Linehan, W Marston, Steinberg, Seth M, Grollman, Frank, Grimes, George, Bernstein, Sarah A, Berzofsky, Jay A, Khleif, Samir N
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843651/
https://www.ncbi.nlm.nih.gov/pubmed/20109232
http://dx.doi.org/10.1186/1479-5876-8-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843651/
https://www.ncbi.nlm.nih.gov/pubmed/20109232
http://dx.doi.org/10.1186/1479-5876-8-8

Ejemplares similares